Engineered immune cells take aim at Hard-to-Treat autoimmune diseases

This early-stage study is testing a new treatment called QT-019C, which uses specially engineered immune cells (CAR T-cells) to target and attack faulty cells that drive autoimmune diseases like lupus and scleroderma. The therapy is given as a one-time infusion and aims to reset the immune system. The study involves 12 adults with severe autoimmune diseases that have not responded to standard treatments. The main goals are to check safety and see if the treatment can control the disease.